Global management consulting and technology firm ZS announced Monday it has entered into a definitive agreement to acquire Trials.ai, an intelligent study design company. The ZS | Trials.ai solution uses artificial intelligence (AI) to help clinical development teams design smarter studies, optimize the participant experience and deliver pharmaceutical therapies to market faster. “Clinical studies too often struggle to find participants and encounter delays, but life sciences companies will now be able to use the ZS | Trials.ai solution to identify risks and opportunities, model operational trade-offs in real time and better see how study decisions will affect participants, sites and sponsors,” said Mike Martin, who leads ZS’s clinical development practice area.
Read the full article: ZS to Acquire Intelligent Study Design Company Trials.ai //
Source: https://www.businesswire.com/news/home/20230206005218/en/ZS-to-Acquire-Intelligent-Study-Design-Company-Trials.ai